<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39320488</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1469-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>152</Volume><PubDate><Year>2024</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Epidemiology and infection</Title><ISOAbbreviation>Epidemiol Infect</ISOAbbreviation></Journal><ArticleTitle>Severe acute respiratory syndrome coronavirus 2-reactive salivary antibody detection in South Carolina emergency healthcare workers, September 2019-March 2020.</ArticleTitle><Pagination><StartPage>e102</StartPage><MedlinePgn>e102</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e102</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0950268824000967</ELocationID><Abstract><AbstractText>On 19 January 2020, the first case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection was identified in the United States, with the first cases in South Carolina confirmed on 06 March 2020. Due to initial limited testing capabilities and potential for asymptomatic transmission, it is possible that SARS-CoV-2 may have been present earlier than previously thought, while the immune status of at-risk populations was unknown. Saliva from 55 South Carolina emergency healthcare workers (EHCWs) was collected from September 2019 to March 2020, pre- and post-healthcare shifts, and stored frozen. To determine the presence of SARS-CoV-2-reactive antibodies, saliva-acquired post-shift was analysed by enzyme-linked immunosorbent assay (ELISA) with a repeat of positive or inconclusive results and follow-up testing of pre-shift samples. Two participants were positive for SARS-CoV-2 N/S1-reactive IgG, confirmed by follow-up testing, with S1 receptor binding domain (RBD)-specific IgG present in one individual. Positive samples were collected from medical students working in emergency medical services (EMSs) in October or November 2019. The presence of detectable anti-SARS-CoV-2 antibodies in 2019 suggests that immune responses to the virus existed in South Carolina, and the United States, in a small percentage of EHCWs prior to the earliest documented coronavirus disease 2019 (COVID-19) cases. These findings suggest the feasibility of saliva as a noninvasive tool for surveillance of emerging outbreaks, and EHCWs represent a high-risk population that should be the focus of infectious disease surveillance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meltzer</LastName><ForeName>Haley C</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>Jane L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fowler</LastName><ForeName>Lauren A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Wake Forest School of Medicine, Charlotte, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Britt</LastName><ForeName>Thomas W</ForeName><Initials>TW</Initials><AffiliationInfo><Affiliation>Department of Psychology, Clemson University, Clemson, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pirrallo</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of South Carolina School of Medicine Greenville, Greenville, SC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grier</LastName><ForeName>Jennifer T</ForeName><Initials>JT</Initials><Identifier Source="ORCID">0000-0002-9331-0280</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, University of South Carolina School of Medicine Greenville, Greenville, SC, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Epidemiol Infect</MedlineTA><NlmUniqueID>8703737</NlmUniqueID><ISSNLinking>0950-2688</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013022" MajorTopicYN="N" Type="Geographic">South Carolina</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="Y">Saliva</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006282" MajorTopicYN="Y">Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ELISA</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibody surveillance</Keyword><Keyword MajorTopicYN="N">emergency healthcare workers</Keyword><Keyword MajorTopicYN="N">saliva</Keyword></KeywordList><CoiStatement>All authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>11</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39320488</ArticleId><ArticleId IdType="pmc">PMC11427973</ArticleId><ArticleId IdType="doi">10.1017/S0950268824000967</ArticleId><ArticleId IdType="pii">S0950268824000967</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schneider EC. (2020) Failing the test – The tragic data gap undermining the U.S. pandemic response. New England Journal of Medicine 383: 299–302.</Citation><ArticleIdList><ArticleId IdType="pubmed">32412704</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna RC, et al. (2020) COVID-19 pandemic: Lessons learned and future directions. Indian Journal of Ophthalmology 68: 703–710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7350475</ArticleId><ArticleId IdType="pubmed">32317432</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. CDC’s World Health Organization (WHO) collaborating center for surveillance, epidemiology and control of influenza. U.S. Department of Health and Human Services. Accessed 02 May 2023.</Citation></Reference><Reference><Citation>Holshue ML, et al. (2020) First case of 2019 novel coronavirus in the United States. New England Journal of Medicine 382: 929–936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092802</ArticleId><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>DHEC. (2020) DHEC is investigating two possible cases of 2019 novel coronavirus in South Carolina – Mar 6, 2020. Accessed 22 July 2022.</Citation></Reference><Reference><Citation>García-García D, et al. (2022) Identification of the first COVID-19 infections in the US using a retrospective analysis (REMEDID). Spatial and Spatio-temporal Epidemiology 42: 100517.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9087146</ArticleId><ArticleId IdType="pubmed">35934325</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema KL, et al. (2021) Estimated SARS-CoV-2 seroprevalence in the US as of September 2020. JAMA internal medicine 181: 450–460.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7686880</ArticleId><ArticleId IdType="pubmed">33231628</ArticleId></ArticleIdList></Reference><Reference><Citation>Basavaraju SV, Patton ME, Grimm K. (2021) Serologic testing of U.S. blood donations to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-reactive antibodies: December 2019-January 2020. Clinical Infectious Diseases 72: e1004–e1009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799215</ArticleId><ArticleId IdType="pubmed">33252659</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorden MA, et al. (2020) Evidence for limited early spread of COVID-19 within the United States, January–February 2020. medRxiv. Published online: 06 April 2020. 10.1101/2020.04.02.20051417v2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.02.20051417v2</ArticleId><ArticleId IdType="pmc">PMC7315848</ArticleId><ArticleId IdType="pubmed">32497028</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizumoto K, et al. (2020) Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance 25: 2000180.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7078829</ArticleId><ArticleId IdType="pubmed">32183930</ArticleId></ArticleIdList></Reference><Reference><Citation>Worobey M, et al. (2016) 1970s and ‘Patient 0’ HIV-1 genomes illuminate early HIV/AIDS history in North America. Nature 539: 98–101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5257289</ArticleId><ArticleId IdType="pubmed">27783600</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukinoki K, et al. (2021) Detection of cross-reactive immunoglobulin A against the severe acute respiratory syndrome-coronavirus-2 spike 1 subunit in saliva. PLoS ONE 16: e0249979.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8610234</ArticleId><ArticleId IdType="pubmed">34813596</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Q, et al. (2021) Global percentage of asymptomatic SARS-CoV-2 infections among the tested population and individuals with confirmed COVID-19 diagnosis: A systematic review and meta-analysis. JAMA Network Open 4: e2137257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8672238</ArticleId><ArticleId IdType="pubmed">34905008</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. (2021) COVID-19 community profile report. U.S. Department of Health &amp; Human Services. Accessed 02 May 2023.</Citation></Reference><Reference><Citation>Nguyen LH, et al. (2020) Risk of COVID-19 among front-line health-care workers and the general community: A prospective cohort study. The Lancet Public Health 5: e475–e483.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7491202</ArticleId><ArticleId IdType="pubmed">32745512</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC. (2022) Cases &amp; deaths among healthcare personnel. U.S. Department of Health and Human Services. Accessed 1 May 2023.</Citation></Reference><Reference><Citation>Wyllie AL, et al. (2020) Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. New England Journal of Medicine 383: 1283–1286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484747</ArticleId><ArticleId IdType="pubmed">32857487</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyllie AL, et al. (2020) Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. New England Journal of Medicine 383: 1283–1286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484747</ArticleId><ArticleId IdType="pubmed">32857487</ArticleId></ArticleIdList></Reference><Reference><Citation>Genelhoud G, et al. (2022) Comparison of SARS-CoV-2 molecular detection in nasopharyngeal swab, saliva, and gargle samples. Diagnostic Microbiology and Infectious Disease 103: 115678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908569</ArticleId><ArticleId IdType="pubmed">35378471</ArticleId></ArticleIdList></Reference><Reference><Citation>d’Amone L, Matzeu G, Omenetto FG. (2021) Stabilization of salivary biomarkers. ACS Biomaterials Science &amp; Engineering 16: 5451–5473.</Citation><ArticleIdList><ArticleId IdType="pubmed">34818885</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo S, et al. (2022) Quantitative detection of anti-SARS-CoV-2 antibodies using indirect ELISA. Lab Medicine 53: 225–234.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8574490</ArticleId><ArticleId IdType="pubmed">34718706</ArticleId></ArticleIdList></Reference><Reference><Citation>Cubuk J, et al. (2021) The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA. Nature Communications 12: 1936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8007728</ArticleId><ArticleId IdType="pubmed">33782395</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei KC, Zhang XD. (2020) Conservation analysis of SARS-CoV-2 spike suggests complicated viral adaptation history from bat to human. Evolution, Medicine and Public Health 2020:290–303.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665476</ArticleId><ArticleId IdType="pubmed">33372198</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchi S, et al. (2021) Characterization of antibody response in asymptomatic and symptomatic SARS-CoV-2 infection. PLoS ONE 16: e0253977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8253392</ArticleId><ArticleId IdType="pubmed">34214116</ArticleId></ArticleIdList></Reference><Reference><Citation>Lei Q, et al. (2021) Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. Allergy: European Journal of Allergy and Clinical Immunology 76: 551–561.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675426</ArticleId><ArticleId IdType="pubmed">33040337</ArticleId></ArticleIdList></Reference><Reference><Citation>Isho B, et al. (2020) Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. Science Immunology 5: eabe5511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8050884</ArticleId><ArticleId IdType="pubmed">33033173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pisanic N, et al. (2021) COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. Journal of Clinical Microbiology 59: e02204-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7771435</ArticleId><ArticleId IdType="pubmed">33067270</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas SN, et al. (2022) Ultrasensitive detection of salivary SARS-CoV-2 IgG antibodies in individuals with natural and COVID-19 vaccine-induced immunity. Scientific Reports 12: 8890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9132168</ArticleId><ArticleId IdType="pubmed">35614113</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy K, et al. (2022) Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individuals. Med 3: 137–153.e3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8770252</ArticleId><ArticleId IdType="pubmed">35075450</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkharaan H, et al. (2021) Persisting salivary IgG against SARS-CoV-2 at 9 months after mild COVID-19: A complementary approach to population surveys. Journal of Infectious Diseases 224: 407–414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8244549</ArticleId><ArticleId IdType="pubmed">33978762</ArticleId></ArticleIdList></Reference><Reference><Citation>Urquia M, et al. (1993) Detection of anti-HIV antibodies in saliva. Journal of Oral Pathology &amp; Medicine 22: 153–156.</Citation><ArticleIdList><ArticleId IdType="pubmed">8315593</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry JV, Perry KR, Mortimer PP. (1987) Sensitive assays for viral antibodies in saliva: An alternative to tests on serum. The Lancet 330: 72–75.</Citation><ArticleIdList><ArticleId IdType="pubmed">2885575</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris-Cunnington MC, et al. (2004) A population-based seroprevalence study of hepatitis A virus using oral fluid in England and Wales. American Journal of Epidemiology 159: 786–794.</Citation><ArticleIdList><ArticleId IdType="pubmed">15051588</ArticleId></ArticleIdList></Reference><Reference><Citation>Archibald DW, et al. (1987) Secretory IgA antibodies to human immunodeficiency virus in the parotid saliva of patients with AIDS and AIDS-related complex. The Journal of Infectious Diseases 155: 793–796.</Citation><ArticleIdList><ArticleId IdType="pubmed">3469280</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceron JJ, et al. (2020) Use of saliva for diagnosis and monitoring the SARS-CoV-2: A general perspective. Journal of Clinical Medicine 9: 1491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7290439</ArticleId><ArticleId IdType="pubmed">32429101</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu S, et al. (2022) Detection of SARS-CoV-2 specific antibodies in saliva samples. Frontiers in Immunology 13: 880154.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9309249</ArticleId><ArticleId IdType="pubmed">35898491</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhakal S, et al. (2023) Reconsideration of antinucleocapsid IgG antibody as a marker of SARS-CoV-2 infection postvaccination for mild COVID-19 patients. Open Forum Infectious Diseases 10: ofac677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9835753</ArticleId><ArticleId IdType="pubmed">36655185</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Elslande J, et al. (2021) Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. Journal of Clinical Virology 136: 104765.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7891078</ArticleId><ArticleId IdType="pubmed">33636554</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. (2012) Surveillance Guidelines for Measles, Rubella and Congenital Rubella Syndrome in the WHO European Region. Accessed 22 June 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">23762964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng KW, et al. (2020) Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 370: 1339–1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857411</ArticleId><ArticleId IdType="pubmed">33159009</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobaño C, et al. (2021) Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: Utility and limitations in seroprevalence and immunity studies. Translational Research 232: 60–74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7879156</ArticleId><ArticleId IdType="pubmed">33582244</ArticleId></ArticleIdList></Reference><Reference><Citation>Ladner JT, et al. (2021) Epitope-resolved profiling of the SARS-CoV-2 antibody response identifies cross-reactivity with endemic human coronaviruses. Cell Reports Medicine 2: 100189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7816965</ArticleId><ArticleId IdType="pubmed">33495758</ArticleId></ArticleIdList></Reference><Reference><Citation>Downton P, Early JO, Gibbs JE. (2020) Circadian rhythms in adaptive immunity. Immunology 161: 268–277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7692252</ArticleId><ArticleId IdType="pubmed">31837013</ArticleId></ArticleIdList></Reference><Reference><Citation>Addetia A, et al. (2020) Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. Journal of Clinical Microbiology 58: e02107-20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7587101</ArticleId><ArticleId IdType="pubmed">32826322</ArticleId></ArticleIdList></Reference><Reference><Citation>Landry ML, Criscuolo J, Peaper DR. (2020) Challenges in use of saliva for detection of SARS CoV-2 RNA in symptomatic outpatients. Journal of Clinical Virology 130: 104567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7392849</ArticleId><ArticleId IdType="pubmed">32750665</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>